Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel recombinant double-function fusion protein, and preparation method and application thereof

A technology of fusion protein and protein, applied in the field of biomedicine

Active Publication Date: 2015-10-14
HUABO BIOPHARM
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Bifunctional fusion protein drugs that can simultaneously bind to TGF-β1 and VEGF and simultaneously block the biological activities induced by these two targets have not been reported so far

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel recombinant double-function fusion protein, and preparation method and application thereof
  • Novel recombinant double-function fusion protein, and preparation method and application thereof
  • Novel recombinant double-function fusion protein, and preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0166] Construction of TβRII-D2-Fc expression vector

[0167] The coding sequence of the TβRII extramembrane region gene consists of 483 nucleotides, as shown in positions 70-552 in SEQ ID NO.:2. The VEGFR1-D2 gene coding sequence consists of 300 nucleotides, as shown in positions 553-852 in SEQ ID NO.:2, including 279 nucleotides of the D2 coding sequence, 15 nucleotides of the upstream flanking sequence, The downstream flanking sequence is 6 nucleotides. 69 signal peptide coding sequences from TβRII (ie, positions 1-69 in SEQ ID NO.: 2) are added to the 5' end of the TβRII outer region, forming 852 nucleotides.

[0168] A "HindIII" gene cloning site and an "EcoRI" gene cloning site were added to the amino terminus of the 852 nucleotides to form a gene fragment containing 873 nucleotides.

[0169] The synthetic product (synthesized by Nanjing GenScript Biotechnology Co., Ltd.) was digested with HindIII / EcoRI and cloned into the pHB-Fc plasmid vector to form the pHB-TbRII-D2...

Embodiment 2

[0174] Expression of TβRII-D2-Fc, D2-TβRII-Fc, TβRII-Fc-D2

[0175] The host cells used for protein expression were CHO-K1 cells (Cat#CCL-61) purchased from ATCC Company. After a series of domestication steps, the cells are domesticated into CHO-K1 cells that can be cultured in suspension in serum-free medium (EX-CELLTM302).

[0176] Using the cells, the plasmids pHB-TβRII-D2-Fc, pHB-D2-TβRII-Fc, and pHB-TβRII-Fc-D2 were respectively transferred into the cells by electroporation. The specific method is: collect the cells in the logarithmic growth phase under sterile conditions, resuspend in the complete medium after centrifugation (1200rpm x5min), and adjust the cell density to 1×10 7 cells / ml. Transfer 350ul of the cell suspension to a 0.4cm electroporation cup, and pulse once under the set electroporation conditions (voltage range 200 to 350V, generally 260V, time about 20ms). Add 10–30ug of plasmid DNA to the electroporation cup containing the cells, mix gently, put the ...

Embodiment 3

[0181] TβRII-D2-Fc and target (VEGF and TGF-β1) binding activity detection

[0182] Enzyme-linked immunosorbent assay (ELISA) method was used to determine the binding properties of the fusion protein and the target (VEGF and TGF-β1). Specific steps are as follows:

[0183] TGF-β1 (Cat: 10804-HNAH, Sino biological Inc.) and VEGF-165 (Cat: 11066-HNAH, Sino biological Inc.) were coated with coating buffer CBS (Sigma-Aldrich Co., Product code: 1001329288C3041-100CAP). .) were diluted to 500ng / ml respectively, and 100ul was added to the ELISA plate (Nunc TM , Cat:442404), 50ng per well. Place the coated plates in a 4°C refrigerator overnight. When detecting, wash the coated plate once with 0.05% PBS-T, and then block it with 3% skimmed milk at room temperature for 1 hour. Add 2-fold serially diluted TbRII-D2-Fc protein (100 nM, 50 nM, 25 nM, up to 0.0244 nM) into the coated plate, 100 ul per well. After incubating at room temperature for one hour, the sample was discarded, was...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

Disclosed are a recombinant bifunctional fusion protein, the preparation method therefor and the use thereof. Specifically, disclosed is a fusion protein having an element A comprising TGF-β receptor extracellular domain, an element B comprising VEGFR1 second extracellular domain D2 and an immunoglobulin element C that are connected in series. The protein can simultaneously bind to two kinds of ligands: VEGF and TGF-β1, and inhibit the biological activity of the ligands. Also provided is the use of the new recombinant bifunctional fusion protein in treating diseases.

Description

technical field [0001] The invention relates to the field of biomedicine. More specifically, the present invention relates to a novel recombinant bifunctional fusion protein and its preparation method and application. Background technique [0002] Diseases such as tumors and liver fibrosis take tens of millions of lives and cause hundreds of millions of dollars in economic losses every year. The combination of TGF-β and VEGFR receptors on the cell membrane surface and the corresponding ligands is an important reason for the occurrence and development of such diseases, so the development of corresponding protein ligand drugs has a good application prospect. [0003] Currently known protein drugs include growth factors, hormone proteins, enzyme proteins, cytokines, interferons, erythropoietin, and fusion proteins. Except for fusion proteins, other protein drugs are homogeneous proteins, that is, they contain only one protein component. However, existing fusion protein drugs...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K19/00C12N15/62C12N15/85C12N5/10C12P21/02A61K38/17A61K47/48A61P35/00A61P1/16
CPCA61K38/00A61P1/16A61P35/00C07K14/495C07K14/71C07K2319/00C07K2319/02
Inventor 田文志
Owner HUABO BIOPHARM
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com